MeiraGTx Holdings plc (MGTX) Stock

MeiraGTx Holdings plc (MGTX) is a Healthcare stock trading at $14.52 (as of 2026-08-20), with a market capitalization of $1.39B and a trailing P/E of 79.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

MeiraGTx Holdings plc is a clinical-stage gene therapy company developing treatments for patients with serious diseases. Its pipeline includes programs for ocular conditions such as inherited retinal disorders and for xerostomia after radiation for head and neck cancer, as well as degenerative and neurodegenerative diseases, including Parkinson’s and amyotrophic lateral sclerosis.

Understand MeiraGTx Holdings plc: how it makes money

MeiraGTx Holdings develops clinical stage gene therapies for serious diseases, including ocular diseases and other conditions, and it currently records revenue mainly from licensing (with service revenue at or near zero).

Because revenue shown here is primarily License Revenue (and Service Revenue is 0), the near-term profit model appears to rely on licensing economics rather than ongoing commercial product sales, while clinical-stage execution is the core driver of future value.

Revenue by segment (latest quarter)
License$0.0B
Service$0.0B

Business quality (Weak): Segment reporting is limited to License Revenue and Service Revenue, and the operating picture is dominated by clinical-stage patient and trial metrics rather than steady commercial revenue.

Bull case

  • Multiple clinical programs in development across ocular diseases (including inherited blindness) and other serious conditions: The company is running phase and dose study activity reflected in multiple patient participation metrics.
  • Evidence of treated patients and clinical responses is tracked in the operating metric set: The company reports counts for treated patients and improvements across vision endpoints.

Bear case

  • Current revenue is essentially zero in the latest quarter, with License Revenue only 0.01 USD_B and Service Revenue at 0.0 USD_B: This implies limited current monetization and makes results highly dependent on future clinical and licensing outcomes.
  • Profitability is very weak on an operating basis, with operating margin of -13930.7 for the latest period: Clinical-stage operating costs can be sustained even when revenue is minimal, increasing financial risk.
Valuation — source: SEC EDGAR (first-party)
Price$14.52
Market Cap$1.39B
P/E Ratio79.3
EV / EBITDA9.5
Price / Book6.46
Price / Sales4.33
FCF Yield-6.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$81.39M
Net Margin-140.3%
Revenue Growth (YoY)144.6%
EPS Growth (YoY)-33.0%
FCF Growth (YoY)-54.1%
Financial Health — source: SEC EDGAR
Altman Z-Score-3.09 (distress)
Valuation vs Sector & Industry
Stock P/E79.3
Sector P/E (Healthcare)21.6
Industry P/E (Pharmaceutical Products)17.2
vs Sector267.3%
vs Industry361.8%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderSanofi ($105.63M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOAlexandria Forbes
Employees375
CountryUS
IPO Date2018-06-08

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Maze Therapeutics, Inc. (MAZE)
  • Vir Biotechnology, Inc. (VIR)
  • Inhibrx Biosciences, Inc. (INBX)
  • Novavax, Inc. (NVAX)
  • Cullinan Therapeutics, Inc. (CGEM)
  • Replimune Group, Inc. (REPL)
  • Monte Rosa Therapeutics, Inc. (GLUE)
  • Vor Biopharma Inc. (VOR)
MGTX earnings history · MGTX institutional & insider holders · MGTX KPIs & operating metrics · MGTX financials · MGTX investor presentations & press releases · MGTX SEC filings · MGTX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.